Sanofi Pasteur: The vaccines division of Sanofi-Aventis Group

Image of adolescent girl.

Help protect your child against meningococcal meningitis by asking your doctor about Menactra vaccine.3,14

What to ask your doctor

If your child has never been vaccinated against meningococcal disease, ask your doctor:

  • "Why was my child never vaccinated for meningococcal disease?"
  • "Can my child get vaccinated now?"

If your child previously received a meningococcal vaccination, ask your doctor:

  • When was my child last vaccinated against meningococcal disease?

Paying for Menactra vaccine

Vaccines are typically covered by most insurance plans. But if you’re underinsured or uninsured, your child can still get Menactra vaccine for little or no fee.20

The Vaccines for Children Program provides vaccines to children that may not otherwise receive them. Most pediatricians in the United States can provide this service. Just ask your doctor.20

If your child doesn’t have a regular doctor, contact your state health department, your local health department, or a neighborhood health clinic about getting Menactra vaccine.20

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another, entirely independent website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Close window and return to site.


Important Safety Information

Indication

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Safety Information

The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur.

Menactra vaccine is contraindicated in persons with a known hypersensitivity (eg, anaphylaxis) to any component of the vaccine. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks. Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions. Vaccination with Menactra vaccine may not protect all individuals.

Before administering Menactra vaccine, please see accompanying full Prescribing Information.